Consensus guidelines for the management of patients with digestive neuroendocrine tumors - Well-differentiated jejunal-ileal tumor/carcinoma

Neuroendocrinology

Volumn 87, Issue 1, 2007, Pages 8-19

  Eriksson, Barbro ^a   Klöppel, Günter ^b   Krenning, Eric ^c   Ahlman, Hakan ^d   Plöckinger, Ursula ^e   Wiedenmann, Bertram ^e   Arnold, Rudolf ^f   Auernhammer, Christoph ^g   Körner, Meike ^h   Rindi, Guido ⁱ   Wildi, Stefan ^j   Caplin, Martyn ^k   Delle Fave, Gianfranco ^l   Ferone, Diego ^m   Goretzki, Peter ⁿ   Hyrdel, Rudolf ^o   Jensen, Robert ^p   Kaltsas, Gregory ^q   Keleştimur, Fahrettin ^r   Kianmanesh, Reza ^s   Komminoth, Paul ^t   Kos Kudła, Beata ^u   Kvols, Larry ^v   Kwekkeboom, Dik ^c   Lopes, José Manuel ^w   Manfredi, Riccardo ^x   McNicol, Anne Marie ^y   Niederle, Bruno ^z   Nilsson, Ola ^d   Nikou, George ^f   Öberg, Kjell ^a   O'Connor, Juan ^aa   O'Toole, Dermot ^ab   Pavel, Marianne ^e   Perren, Aurel ^j   Ramage, John ^ac   Ricke, Jens ^ad   Ruszniewski, Philippe ^ae   Scarpa, Aldo ^af   Scoazec, Jean Yves ^ag   Sevilla Garcia, Maria Isabel ^ah   Steinmüller, Thomas ^ai   Taal, Babs ^aj   Vullierme, Marie Pierre ^ae   Yao, James C ^ak   more..

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF KIEL   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Ludwig Maximilians Universität München ^*  (Greece)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF PARMA   (Italy)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k ROYAL FREE HOSPITAL   (United Kingdom)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ Lukaskrankenhaus GmbH   (Germany)

^o Martinska Fakultna Nemocnica   (Slovakia)

^p NATIONAL INSTITUTES OF HEALTH   (United States)

^q G GENNIMATAS GENERAL HOSPITAL   (Greece)

^r ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^s HÔPITAL LOUIS MOURIER   (France)

^t Kantonsspital Baden   (Switzerland)

^u MEDICAL UNIVERSITY OF SILESIA   (Poland)

^v H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^w UNIVERSITY OF PORTO   (Portugal)

^x Istituto di Radiologia   (Italy)

^y GLASGOW ROYAL INFIRMARY   (United Kingdom)

^z UNIVERSITY OF VIENNA   (Austria)

^aa INSTITUTO ALEXANDER FLEMING   (Argentina)

^ab ANGERS UNIVERSITY HOSPITAL   (France)

^ac NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^ad OTTO VON GUERICKE UNIVERSITY   (Germany)

^ae BEAUJON HOSPITAL   (France)

^af UNIVERSITY OF VERONA   (Italy)

^ag EDOUARD HERRIOT HOSPITAL   (France)

^ah HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^ai DRK KLINIKEN BERLIN WESTEND   (Germany)

^aj Netherlands Cancer Centre   (Netherlands)

^ak UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN C 11; ALPHA INTERFERON; ANGIOPEPTIN; ANTIBIOTIC AGENT; COLESTYRAMINE; DACARBAZINE; DIHYDROXYPHENYLALANINE F 18; DIHYDROXYPHENYLALANINE OCTREOTATE LU 177; DIHYDROXYPHENYLALANINE OCTREOTIDE Y 90; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; INTERFERON; LOPERAMIDE; MORPHINE DERIVATIVE; OCTREOTIDE; PEGINTERFERON ALPHA; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AUTOIMMUNE DISEASE; AUTOPSY; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURGERY; CARCINOID SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENDOSCOPY; EVIDENCE BASED MEDICINE; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; GALLSTONE; GENETICS; HEART SURGERY; HUMAN; ILEUM CANCER; ILEUM TUMOR; INTESTINE TUMOR; JEJUNUM CANCER; JEJUNUM TUMOR; LABORATORY TEST; LIVER METASTASIS; LIVER TOXICITY; LYMPH NODE METASTASIS; MENTAL DISEASE; MONOTHERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STEATORRHEA; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

CARCINOMA, NEUROENDOCRINE; CONSENSUS; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 37349069330     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111034     Document Type: Conference Paper

References (117)

1. Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
2. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999;340:858-868.
3. Burke AP, Thomas RM, Elsayed AM, Sobin LH: Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997;79:1086-1093.
4. Peck JJ, Shields AB, Boyden AM, Dworkin LA, Nadal JW: Carcinoid tumors of the ileum. Am J Surg 1983;146:124-132.
5. Modlin IM, Sandor A: An analysis of 8,305 cases of carcinoid tumors. Cancer 1997;79:813-829.
6. Loftus JP, van Heerden JA: Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995;28:317-336.
7. Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36:560-569.
8. Solcia E KG, Sobin LH, in collaboration with 9 pathologists from 4 countries: Histological Typing of Endocrine Tumors, ed 2. WHO International Histological Classification of Tumors. Berlin, Springer, 2000.
9. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976;84:322-330.
10. Strodel WE, Talpos G, Eckhauser F, Thompson N: Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983;118:391-397.
11. Marshall JB, Bodnarchuk G: Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993;16:123-129.
12. McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994;81:1007-1009.
13. Arnold R, Rinke A, Klose KJ, et al: Octreotide versus octreotide plus interferon-α in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-771.
14. Oberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110-120.
15. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502-1522.
16. Creutzfeldt W: Carcinoid tumors: development of our knowledge. World J Surg 1996;20:126-131.
17. Oberg K: The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993;22:941-952.
18. Ahlman H, Westberg G, Wangberg B, et al: Treatment of liver metastases of carcinoid tumors. World J Surg 1996;20:196-202.
19. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-β and fibroblast growth factor. Cancer 2003;97:1609-1615.
20. Norheim I, Oberg K, Theodorsson-Norheim E, et al: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206:115-125.
21. Makridis C, Rastad J, Oberg K, Akerstrom G: Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 1996;20:900-907.
22. Westberg G, Wangberg B, Ahlman H, Bergh CH, Beckman-Suurkula M, Caidahl K: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001;88:865-872.
23. 3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716-731.
24. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757.
25. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001;37:8-17.
26. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15-27.
27. Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT: MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 2001;14:261-269.
28. 11C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-3400.
29. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-734.
30. Van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG: Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006;64:66-72.
31. Swain P: Wireless capsule endoscopy. Gut 2003;52(suppl 4):48-50.
32. Oberg K, Stridsberg M: Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000;482:329-337.
33. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003;10:459-462.
34. Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986;81:41-48.
35. Eriksson B, Oberg K: Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991;30:477-483.
36. Hamilton SR AL: Tumors of the digestive system. Pathology and Genetics. WHO Classification of Tumours. Lyon, ARC Press, 2000.
37. Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
38. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-2210.
39. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2001;94:444-448.
40. Akerstrom G, Makridis C, Johansson H: Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-553.
41. Rothmund M, Kisker O: Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994;55(suppl 3):86-91.
42. Ahlman H, Wangberg B, Jansson S, et al: Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000;62(suppl 1):59-68.
43. Makridis C, Oberg K, Juhlin C, et al: Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-384.
44. Norton JA: Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55(suppl 3):98-103.
45. Goede AC, Winslet MC: Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 2003;5:123-128.
46. Frilling A, Rogiers X, Malago M, Liedke OM, Kaun M, Broelsch CE: Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998;383:62-70.
47. Lehnert T, Knaebel HP: Diagnosis and therapy of liver metastases of neuroendocrine tumors (in German). Chirurg 1997;68:122-131.
48. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88-93.
49. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-43.
50. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
51. Chamberlain RS, Canes D, Brown KT, et al: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432-445.
52. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057-1065.
53. Soreide O, Berstad T, Bakka A, et al: Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992;111:48-54.
54. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH: Life history of the carcinoid tumor of the small intestine. Cancer 1961;14:901-912.
55. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y: Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908-915.
56. Chung MH, Pisegna J, Spirt M, et al: Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130:954-962.
57. Wangberg B, Westberg G, Tylen U, et al: Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996;20:892-899.
58. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-1096.
59. Eriksson B, Oberg K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10(suppl 2):S31-S38.
60. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041-1044.
61. Wymenga AN, Eriksson B, Salmela PI, et al: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
62. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-3281.
63. Di Bartolomeo M, Bajetta E, Buzzoni R, et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-408.
64. Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-438.
65. Aparicio T, Ducreux M, Baudin E, et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-1019.
66. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776.
67. Ruszniewski P, Ducreux M, Chayvialle JA, et al: Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-283.
68. Tomassetti P, Migliori M, Gullo L: Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998;93:1468-1471.
69. Tomassetti P, Migliori M, Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-560.
70. Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-2696.
71. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606.
72. Ricci S, Antonuzzo A, Galli L, et al: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127-1130.
73. Leong WL, Pasieka JL: Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002;79:180-187.
74. Saltz L, Trochanowski B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-248.
75. Plockinger U, Dienemann D, Quabbe HJ: Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990;71:1658-1662.
76. Oberg K, Norheim I, Lind E, et al: Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 1986;70:1297-1304.
77. Valimaki M, Jarvinen H, Salmela P, Sane T, Sjoblom SM, Pelkonen R: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991;67:547-549.
78. Doberauer C, Mengelkoch B, Kloke O, Wandl U, Niederle N: Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon-α. Acta Oncol 1991;30:603-605.
79. Creutzfeldt W, Bartsch HH, Jacubaschke U, Stockmann F: Treatment of gastrointestinal endocrine tumours with interferon-α and octreotide. Acta Oncol 1991;30:529-535.
80. Moertel CG, Rubin J, Kvols LK: Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989;7:865-868.
81. Janson ET, Ronnblom L, Ahlstrom H, et al: Treatment with α-interferon versus α-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992;3:635-638.
82. Oberg K, Alm G, Magnusson A, et al: Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81:531-535.
83. Smith DB, Scarffe JH, Wagstaff J, Johnston RJ: Phase II trial of rDNA alfa-2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 1987;71:1265-1266.
84. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE: Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647-1650.
85. 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian Carcinoid Study. Scand J Gastroenterol 1995;30:789-796.
86. Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van Oosterom AT: Long-term results of continuous treatment with recombinant interferon-α in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anticancer Drugs 1996;7:175-181.
87. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumors. Acta Oncol 1991;30:519-522.
88. Nold R, Frank M, Kajdan U, Trost U, Klose KJ, Arnold R: Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-α (in German). Z Gastroenterol 1994;32:193-197.
89. Kolby L, Persson G, Franzen S, Ahren B: Randomized clinical trial of the effect of interferon-α on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693.
90. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R: Combination therapy with octreotide and α-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-1387.
91. Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(suppl 2):S111-S114.
92. Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62(suppl 1):73-78.
93. Pelley RJ, Bukowski RM: Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Curr Opin Oncol 1999;11:32-37.
94. De Jong M, Breeman WA, Bernard HF, et al: Therapy of neuroendocrine tumors with radiolabeled somatostatin analogues. Q J Nucl Med 1999;43:356-366.
95. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-441.
96. Stolz B, Smith-Jones P, Albert R, et al: Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996;57(suppl 1):17-21.
97. Valkema R, De Jong M, Bakker WH, et al: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-122.
98. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-945.
99. 90Y-DOTATOC. J Nucl Med 2002;43:610-616.
100. 90Y-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 2002;29(suppl):S100.
101. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-155.
102. Virgolini I, Traub T, Novotny C, et al: Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002;8:1781-1807.
103. 3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841-1846.
104. Chinol M, Bodei L, Cremonesi M, Paganelli G: Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32:141-147.
105. 3-octreotide. Eur J Nucl Med 2001;28:426-434.
106. 90Y-SMT487 (Octreo-Ther) in patients with somatostatin receptor-positive tumors. J Nucl Med 2002;5(suppl):33P.
107. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-216.
108. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP: Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
109. 90Y-SMT487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556-1560.
110. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-633.
111. 0]octreotide in patients. Eur J Nucl Med 2001;28:1319-1325.
112. 177Lu-labeled analogs only. J Nucl Med 2002:123-124.
113. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422.
114. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762.
115. Jacobsen MB, Nitter-Hauge S, Bryde PE, Hanssen LE: Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J 1995;16:263-268.
116. Gustafsson BI, Tommeras K, Nordrum I, et al: Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-1522.
117. Zuetenhorst JM, Korse CM, Bonfrer JM, Bakker RH, Taal BG: Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004;90:2073-2079.